Mark Kvarta

19PUBLICATIONS
30CO-AUTHORS
Biologically active moleculesPharmaceutical delivery technologiesPharmacogenomicsPersonality and individual differencesMetabolic medicine
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Sep 07, 2026
The Antidepressant Effects of the mGlu2/3 Receptor Antagonist TS-161 in Treatment-Resistant Depression: A Phase IIa Proof-of-Concept Clinical Trial.

|Jul 28, 2026
Convergent neuroimmune signaling underlying rapid antidepressant response to ketamine and psychedelics.

|Jul 24, 2026
Time-dependent effects of rapid-acting antidepressants in iPSC-derived neurons from treatment-resistant depression and healthy volunteers.

|Feb 26, 2026
Time-Dependent Effects of Rapid-Acting Antidepressants in iPSC-Derived Neurons from Treatment-Resistant Depression and Healthy Volunteers.

Jenessa Johnston, Greg Jones, Shiyong Peng

|Jul 12, 2024
Esketamine in depression: putative biomarkers from clinical research.

Jenessa N Johnston, Carlos A Zarate, Mark D Kvarta

|Dec 08, 2023
Effects of independent versus dependent stressful life events on major symptom domains of schizophrenia.

Yizhou Ma, Joshua Chiappelli, Mark D Kvarta

Pageof 4

Frequent Collaborators

5 joint publications

Francis McMahon

4 joint publications

Eric L Goldwaser

4 joint publications

Heather Bruce

3 joint publications

Jenessa N Johnston